HIGHLIGHTS
SUMMARY
POLE wildtype (POLEwt) EC with loss of expression in one of the MMR proteins are classified as MMR-deficient (MMRd) EC, independent of p53 IHC status. The final step in the diagnostic algorithm uses p53 IHC to distinguish between EC without a specific molecular profile (NSMP) and p53-abnormal (p53abn) EC. Recent studies showed that abnormal p53 IHC reliably identifies cases with TP53 mutation in ovarian carcinoma (100% specificity and 96% sensitivity) and in EC biopsies (94% specificity and 91% sensitivity)7,8. Other tumors show complete absence of p53 expression (‘null mutant` pattern . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.